ADHD, nicotine and vaping

Many adults with ADHD say that nicotine helps them feel focused, and many also find it unusually hard to give up. Research supports the link, and it raises reasonable questions: are people treating their own symptoms, does ADHD medication change the risk, and which quit options make sense? This page goes through the evidence. It separates what applies to adults from what comes from youth studies, especially on vaping.

How common is it?

The most reliable data follow children forward in time. A 2011 meta-analysis by Lee and colleagues found that children with ADHD were about twice as likely to have ever used nicotine (odds ratio 2.08), and nearly three times as likely to report nicotine dependence in adolescence or adulthood (odds ratio 2.82). A 2018 review reports that youth with ADHD are 2 to 3 times more likely to smoke than their peers, start earlier and move faster to regular use and dependence.

Adult figures are older and smaller. In a 1995 study of 71 adult patients with ADHD, 42% of men and 38% of women were current smokers, compared with 28.1% and 23.5% in the 1991 general population. Their quit ratio was 29%, compared with 48.5% in the general population. Smoking rates have changed a great deal since then, so those numbers are useful mainly for the gap they show.

Is it self-medication?

The 2018 systematic review by van Amsterdam and colleagues weighed several explanations: self-medication, ADHD traits that make starting easier and quitting harder, peer pressure, and shared genes or environment. It concluded that smoking itself may be explained by a combination of imitation, peer pressure and ADHD traits, while nicotine dependence in ADHD is currently explained most strongly by self-medication. The authors add that this still awaits confirmation from long-term naturalistic studies.

Other evidence fills in parts of the picture:

• Genetics. A 2021 Mendelian randomization study by Treur and colleagues found evidence that genetic liability to ADHD increases the chance of starting smoking and smoking more heavily, and reduces the chance of quitting. Evidence in the other direction was weak.
• Withdrawal. In a 12-day abstinence study of 40 adult smokers, withdrawal symptoms were generally more severe in those with ADHD, especially women, in the first 5 days. ADHD symptom scales did not show the same difference between groups.
• Attention during abstinence. In a laboratory study of 33 adult smokers, a day without smoking reduced inhibitory control in both those with and without ADHD, so this is partly a general nicotine effect.
• Overlap in symptoms. A secondary analysis of a cessation trial found withdrawal symptoms and craving overlapped more strongly with ADHD symptoms after quitting, so quitting can make it harder to tell what is withdrawal and what is ADHD.

Feeling sharper after nicotine does not point to ADHD on its own. Going without nicotine can itself reduce performance, as that laboratory study shows, so some of the lift may be relief from withdrawal. The guide's page on ADHD or substance effects looks at how evaluators separate these.

Does ADHD treatment change smoking risk?

The evidence differs depending on the question.

Put simply, treating ADHD may help lower smoking risk over time, but no one should count on a stimulant as a way to quit. The association may partly reflect who stays in consistent treatment. As of November 2026, Cochrane has registered a protocol for a review of smoking cessation interventions in adults with ADHD or autism, but no results were available when this page was written.

Quit options

The US Preventive Services Task Force recommends that clinicians ask all adults about tobacco use, advise them to stop, and provide behavioral support and FDA-approved medication to nonpregnant adults who use tobacco. Pregnant people have different recommendations, so they should ask their clinician. The FDA says approved or cleared products can even double your chance of quitting successfully. Options include:

• Nicotine replacement. Patches, gum and lozenges are sold over the counter for people 18 and older. Nasal spray and inhaler forms are prescription.
• Varenicline. The label indicates it as an aid to smoking cessation. Postmarketing reports include serious neuropsychiatric events. A large randomized study found no increase in such events in people without a psychiatric history; in people with a psychiatric history, event rates were higher across all active treatments compared with placebo. The label also warns about seizures, increased effects of alcohol, accidental injury, sleepwalking, angioedema and serious skin reactions, notes that patients with heart disease may be at increased risk of cardiovascular events, and says combining it with the nicotine patch led to a high rate of discontinuation.
• Bupropion. The sustained-release label indicates it as an aid to smoking cessation. Use for ADHD is off-label, and the page on bupropion for ADHD covers that evidence. The label carries a boxed warning about suicidal thoughts and behaviors in children, adolescents and young adults. Its seizure risk is dose-related. It is contraindicated with a seizure disorder, with a current or prior diagnosis of bulimia or anorexia, and during abrupt discontinuation of alcohol, benzodiazepines, barbiturates or antiepileptic drugs. It is also contraindicated with MAOIs, including linezolid and intravenous methylene blue, and with known bupropion allergy. Stop it and contact a clinician if agitation, depressed mood or unusual behavior or thinking occurs. It can raise blood pressure, particularly with nicotine replacement, and it inhibits the liver enzyme CYP2D6, which can affect other medications.

Bring up any quit plan with the person who prescribes your ADHD medication, since it may affect blood pressure, sleep or other medicines. Mental health history matters when choosing a quit medication. Anyone who develops suicidal thoughts should get help right away by calling or texting 988. If you use other substances too, read ADHD and substance use.

Vaping: a caveat about the evidence

Most vaping research in ADHD is in young people, and it may not carry over to older adults.

• In a survey of 195,443 US undergraduate and graduate students aged 18 to 39, an ADHD history carried an adjusted odds ratio of 1.72 for current e-cigarette use.
• A 2021 systematic review of 40 studies found youth e-cigarette use linked to greater mental health problems. Because many studies were cross-sectional, direction remains uncertain.
• CDC reports 1.63 million US middle and high school students (5.9%) used e-cigarettes in 2024, and says nicotine can harm the parts of an adolescent's brain that control attention, learning, mood and impulse control.

For adults who smoke, the evidence on vaping as a quit aid is unsettled. CDC says e-cigarettes may have potential benefit for adults who smoke and are not pregnant, if used as a complete substitute for smoked tobacco, but also that there are no safe tobacco products and that more research is needed. As of November 2026, CDC states that no e-cigarette has been approved by the FDA as a smoking cessation aid. The US Preventive Services Task Force found the evidence insufficient to assess benefits and harms for cessation, and it says clinicians should direct patients to interventions with proven effectiveness and established safety.

No studies testing vaping as a treatment for adult ADHD symptoms were found for this page, and it should not be treated as one.

Raising it in an evaluation

Mention nicotine in any form: cigarettes, vapes, pouches and gum. Note how much you use, when you started, what happens when you stop and whether you use it mainly to concentrate. The guide on preparing for an adult ADHD evaluation has a fuller list. Dr. Shershow's evaluation asks about substances as part of the health history. Dr. Shershow evaluates and treats adults with ADHD located in New York or New Jersey. You can read more about the adult ADHD evaluation.